Hypomethylating agent
From Wikipedia, the free encyclopedia
A hypomethylating agent is a drug that inhibits DNA methylation.
The term "demethylating agent" is also used.[1]
They are undergoing investigation for use in the treatment of tumors.[2]
Examples include:
[edit] See also
[edit] References
- ^ Garcia-Manero G (November 2008). "Demethylating agents in myeloid malignancies". Curr Opin Oncol 20 (6): 705–10. doi:10.1097/CCO.0b013e328313699c. PMID 18841054. http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?an=00001622-200811000-00016.
- ^ Hambach L, Ling KW, Pool J, et al. (December 2008). "Hypomethylating drugs convert HA-1 negative solid tumors into targets for stem cell based immunotherapy". Blood 113 (12): 2715–22. doi:10.1182/blood-2008-05-158956. PMID 19096014. http://www.bloodjournal.org/cgi/pmidlookup?view=long&pmid=19096014.
- ^ Aribi A, Borthakur G, Ravandi F, et al. (February 2007). "Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia". Cancer 109 (4): 713–7. doi:10.1002/cncr.22457. PMID 17219444.
- ^ De Padua Silva L, de Lima M, Kantarjian H, et al. (January 2009). "Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome". Bone Marrow Transplant. 43 (11): 839–43. doi:10.1038/bmt.2008.400. PMID 19151791.
- ^ Garcia-Manero G, Stoltz ML, Ward MR, Kantarjian H, Sharma S (September 2008). "A pilot pharmacokinetic study of oral azacitidine". Leukemia 22 (9): 1680–4. doi:10.1038/leu.2008.145. PMID 18548103.
| This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |

